

Abstract

The invention relates to the use of peripheral-blood mononuclear cells that have been stimulated via cascade
5 priming (CAPRI cells) for the purpose of providing an agent
for the treatment of cancerous diseases. The CAPRI cells
may also be administered in combination with CD3-activated
cells.